162 related articles for article (PubMed ID: 17013434)
1. [Thalidomide in treatment of connective diseases and vasculities].
Maruotti N; Cantatore FP; Ribatti D
Reumatismo; 2006; 58(3):187-90. PubMed ID: 17013434
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide: focus on its employment in rheumatologic diseases.
Ossandon A; Cassarà EA; Priori R; Valesini G
Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207
[TBL] [Abstract][Full Text] [Related]
3. [Thalidomide: the revival].
Grosbois B; Duguet C
Rev Med Interne; 2001 Jan; 22(1):5-7. PubMed ID: 11218298
[No Abstract] [Full Text] [Related]
4. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
5. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide in Behçet's disease.
Shek LP; Lim DL
Biomed Pharmacother; 2002 Feb; 56(1):31-5. PubMed ID: 11908493
[TBL] [Abstract][Full Text] [Related]
7. [Thalidomide and thrombosis: three observations].
Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL
Presse Med; 2001 Jun; 30(20):1008-9. PubMed ID: 11433688
[No Abstract] [Full Text] [Related]
8. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide--a new prospective therapy in rheumatology and transplantation].
Pałgan K; Pałgan I; Dziedziczko A
Wiad Lek; 2003; 56(11-12):574-6. PubMed ID: 15058168
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide: a remarkable comeback.
Jacobson JM
Expert Opin Pharmacother; 2000 May; 1(4):849-63. PubMed ID: 11249521
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms.
Domingo S; Solé C; Moliné T; Ferrer B; Ordi-Ros J; Cortés-Hernández J
Dermatology; 2020; 236(5):467-476. PubMed ID: 32659758
[TBL] [Abstract][Full Text] [Related]
12. Dermatologic and nondermatologic uses of thalidomide.
Nasca MR; Micali G; Cheigh NH; West LE; West DP
Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Walchner M; Meurer M; Plewig G; Messer G
Int J Dermatol; 2000 May; 39(5):383-8. PubMed ID: 10849134
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.
Direskeneli H; Ergun T; Yavuz S; Hamuryudan V; Eksioglu-Demiralp E
Clin Rheumatol; 2008 Mar; 27(3):373-5. PubMed ID: 18034203
[TBL] [Abstract][Full Text] [Related]
16. [Weight gain during treatment with thalidomide: a case report].
Comte H; Béné J; Auffret M; Gautier S; Salle-Staumont D
Therapie; 2014; 69(5):457-9. PubMed ID: 25285366
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide responsiveness in an infant with Behçet's syndrome.
Shek LP; Lee YS; Lee BW; Lehman TJ
Pediatrics; 1999 Jun; 103(6 Pt 1):1295-7. PubMed ID: 10353947
[TBL] [Abstract][Full Text] [Related]
18. Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome.
Zhang L; Au S; Aronson IK
Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526013
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
20. The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
Strupp C; Germing U; Aivado M; Kündgen A; Fenk R; Hünerlitürkoglu A; Kobbe G; Haas R; Gattermann N
Leuk Lymphoma; 2005 Jul; 46(7):999-1006. PubMed ID: 16019550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
